Shares of CRISPR Therapeutics CRSP have lost more than 30% in the past year. Though the stock soared at the onset of 2024, ...
CRISPR Therapeutics AG (NASDAQ:CRSP), a leading biotechnology company specializing in gene-based medicines with a market capitalization of $3.45 billion, stands at a critical juncture as it navigates ...
"We’re in very different place," the CEO of Editas says, citing the CRISPR pioneer's plans to get its first treatments into ...
CRISPR Therapeutics is a mid-stage biotech ... Investor enthusiasm about technology and growth stocks, and the economic environment ahead, drove the momentum. After all, the artificial ...
A look at Intellia Therapeutics, Inc. and Editas Medicine, Inc., including their restructuring and pipeline prioritization.
It feels fantastic,” said Blau, who thanked her lab members and colleagues for their support and dedication. “This ...
AZoLifeSciences on MSN2d
Integrating CRISPR and biomaterials engineering: Paving the way for safer gene therapiesLehigh University bioenginering researcher Tomas Gonzalez-Fernandez recently secured funding through the National Science ...
The new Express License service removes barriers to accessing this transformative gene editing technology for startups.An ...
3d
Bengaluru-based biotechnology startup, CrisprBits Private Limited, has inaugurated a CRISPR gene editing and diagnostics ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback